Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
codavax-rsv
- Development stage
- Phase 1
- Lead developer
- Codagenix
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
CodaVax-RSV is a live-attenuated, intranasal vaccine candidate developed to prevent respiratory syncytial virus (RSV) infections in infants, young children, and adults. The vaccine is engineered using hundreds of strategic genomic modifications that slow viral replication, resulting in a genetically stable and attenuated RSV virus that expresses all RSV proteins as antigens. This design aims to elicit both mucosal and cellular immune responses, including neutralizing antibodies and CD8-positive T lymphocyte activation. CodaVax-RSV has demonstrated safety and immunogenicity in Phase 1 studies involving older adults and is currently being evaluated in pediatric populations. The primary indication for CodaVax-RSV is the prevention of RSV infection[1][2][4][5].
- Brand names
- codavax-rsv
- Other names
- live attenuated rsv vaccine codagenix
02
Targets
Respiratory syncytial virus-specific T-cell receptorRSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on codavax-rsv.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on codavax-rsv.